Splenic marginal-zone lymphoma: a distinct clinical and pathological entity
View abstract on PubMed
Summary
This summary is machine-generated.Splenic marginal-zone lymphoma (splenic MZL) is an indolent B-cell lymphoma. Splenectomy is the primary treatment, improving quality of life and survival despite not achieving complete remission.
Area Of Science
- Hematology
- Oncology
- Immunology
Background
- Splenic marginal-zone lymphoma (splenic MZL) is an indolent B-cell neoplasm.
- Typically presents with splenomegaly, bone marrow, and peripheral blood involvement.
- Extranodal and lymph node involvement is rare.
Purpose Of The Study
- To describe the characteristics, prognosis, and treatment of splenic MZL.
- To highlight factors associated with patient outcomes.
- To establish splenectomy as a primary therapeutic approach.
Main Methods
- Review of World Health Organization classification criteria for splenic MZL.
- Analysis of immunophenotypic and genetic features.
- Evaluation of prognostic factors and treatment outcomes.
Main Results
- Splenic MZL exhibits micronodular splenic infiltration with characteristic immunophenotype (IgM+, CD5-, CD10-, CD23-).
- Common genetic abnormality involves 7q22-7q32 deletions.
- Immunological events (hemolytic anemia, immune thrombocytopenia) and monoclonal component correlate with shorter survival.
- Splenectomy leads to partial remission, improving cytopenia, quality of life, and survival.
Conclusions
- Splenic MZL is an indolent lymphoma with variable prognosis.
- Immunological complications and monoclonal protein presence are adverse prognostic indicators.
- Splenectomy is the recommended first-line treatment for splenic MZL, offering significant clinical benefits.